{"id":1014553,"date":"2026-10-28T07:57:08","date_gmt":"2026-10-28T11:57:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/"},"modified":"2026-10-28T07:57:08","modified_gmt":"2026-10-28T11:57:08","slug":"pyxis-oncology-to-participate-in-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/","title":{"rendered":"Pyxis Oncology to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Oct.  28, 2026  (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, will participate in fireside chats at two upcoming conferences.<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Guggenheim 3rd Annual Healthcare Innovation Conference <\/strong>in Boston, MA on Monday, November 9, 2026, at 9:00 a.m. ET.<\/p>\n<\/li>\n<li>\n          <strong>Stifel 2026 Healthcare Conference<\/strong> in New York, NY on Tuesday, November 10, 2026, at 4:40 p.m. ET.<\/p>\n<\/li>\n<\/ul>\n<p>Live\u00a0webcasts\u00a0and\u00a0replays\u00a0of the fireside chats\u00a0will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fki1QeImAYLXbClCvK4KJ5mkKP6FckuQnXnTrHNS9Po6sPQGbxlUS6LU45_JppRGGwD7_V-8y6sDBtDtpHNvPy4Hm6Mz66fGxxz4NnQhiZY=\" rel=\"nofollow\" target=\"_blank\">ir.pyxisoncology.com<\/a>.<\/p>\n<p>\n        <strong>About Pyxis Oncology, Inc.<\/strong><br \/>\n        <br \/>Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R\/M HNSCC) and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) in a Phase 1\/2 clinical study in patients with R\/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R\/M HNSCC and contributing to meaningful progress in cancer treatment.<\/p>\n<p>MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R\/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.<\/p>\n<p>KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p>To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EWdbWK_vuXHeJQ12uVfc_BnWHz9Mv-HuDv4Ii-H9vlH37l-Nbpr_Phu4-d0wEHSL77INqpmSFcZ1dsJLC5FNzAj76NKZkP560QmD8PST8TeOPUtDUgDySKuo5yxazWsAGTUUlxHmIse9F7CdNtne_LQ9XJh9QLxeN7qC5AxXrgratBZ4RH929eK7yVzZs36Ksndu9pYC9y6_C6BRsLb_Vu80YXZ0ak7giLH7xyiUMNKn85o3B4HnYfoVq6PW_J-WLbFf7LyVqMEg0CJu4-t8tw==\" rel=\"nofollow\" target=\"_blank\">www.pyxisoncology.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fGTP519Kp4HknwSkQzb1JmMlw0ilDNZ79Ipe3cWBj5efMO_Pyopjn7UzSTdEiF1RsERgyllrQ-OZ27exGkqyIJsGn1Qa1SMJfFBaGna3kmJ2aAC2kOISmLZf-6T3kWrQxMr4vmORWZBvX4io4ecT-XhKoxayxrYUpDH6QxnojknS6EObalALgpsFfykyQYcEx6Gk0XjXxei_tRx0LuZTA_4RUnej6J06rk5feAz83AnU9-Wgjo5_gWevYM7J9zlx\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Pyxis Oncology Contact<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iBsailOwYv6c1NVSasE-Mjxef1j8Pq7D-8x6u8Gr6gcrVfhOP6eg9P68dBFxkqib3VY7rmHDWi1OfV382o8_1OFwqjpPKiHDq9ZwRK0z7R8=\" rel=\"nofollow\" target=\"_blank\">IR@pyxisoncology.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODZmZmQ2NDMtYjA0OC00ZjA5LTkxODMtNTA2NWNiN2EwMjExLTEyMjA3ODItMjAyNi0xMC0yOC1lbg==\/tiny\/Pyxis-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, will participate in fireside chats at two upcoming conferences. Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Monday, November 9, 2026, at 9:00 a.m. ET. Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 4:40 p.m. ET. Live\u00a0webcasts\u00a0and\u00a0replays\u00a0of the fireside chats\u00a0will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website,\u00a0ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s lead candidate, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pyxis Oncology to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1014553","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, will participate in fireside chats at two upcoming conferences. Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Monday, November 9, 2026, at 9:00 a.m. ET. Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 4:40 p.m. ET. Live\u00a0webcasts\u00a0and\u00a0replays\u00a0of the fireside chats\u00a0will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website,\u00a0ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s lead candidate, &hellip; Continue reading &quot;Pyxis Oncology to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-28T11:57:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pyxis Oncology to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-10-28T11:57:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"wordCount\":359,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/\",\"name\":\"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=\",\"datePublished\":\"2026-10-28T11:57:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pyxis Oncology to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, will participate in fireside chats at two upcoming conferences. Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Monday, November 9, 2026, at 9:00 a.m. ET. Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 4:40 p.m. ET. Live\u00a0webcasts\u00a0and\u00a0replays\u00a0of the fireside chats\u00a0will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website,\u00a0ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s lead candidate, &hellip; Continue reading \"Pyxis Oncology to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-28T11:57:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pyxis Oncology to Participate in Upcoming Investor Conferences","datePublished":"2026-10-28T11:57:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/"},"wordCount":359,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/","name":"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=","datePublished":"2026-10-28T11:57:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxNSM3OTE2Mjk1IzIyMDkyMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pyxis Oncology to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1014553"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014553\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1014553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1014553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1014553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}